NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00256776 2021-10-18
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
European Society for Blood and Marrow Transplantation
Phase 3 Terminated
NCT00124579 2018-08-09
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Terminated
NCT00376961 2017-11-06
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
SWOG Cancer Research Network
Phase 2 Completed